Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$397.49 USD

397.49
467,049

+14.72 (3.85%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $397.55 +0.06 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks News

Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?

Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Arena Pharmaceuticals' (ARNA) Q2 Loss Widens, Revenues Meet

Arena Pharmaceuticals (ARNA) incurs wider-than-expected loss in the second quarter of 2019 while revenues are in line.

United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Down Y/Y

United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.

United Therapeutics (UTHR) Q2 Earnings and Revenues Beat Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 51.25% and 12.60%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Arena Initiates Dosing in Pivotal Colitis Study on Etrasimod

Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.

Arena Pharmaceuticals' (ARNA) Loss Widens in Q1 But Stock Up

Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.

United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.

United Therapeutics (UTHR) Beats Q1 Earnings and Revenue Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 35.61% and 9.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

United Therapeutics Discontinues PAH Drug After Study Fails

United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.

Company News For Apr 9, 2019

Companies In The News Are: SNE, DLTR, UTHR, TWOU

United Therapeutics (UTHR) Down 7.2% Since Last Earnings Report: Can It Rebound?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.

Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues

Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.

Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics (UTHR) Up 2% Since Last Earnings Report: Can It Continue?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: GILD's Drug Wins Nod in China, Arena Up On Licensing Deal

Regulatory news and licensing contracts are key highlights in the biotech sector this week.

Arena (ARNA) Out-Licenses Rights to PAH Drug, Stock Up 22%

Arena (ARNA) inks a deal to out-license global rights to its phase III candidate, ralinepag, to United Therapeutics. Shares of the company rally 22% following this news.

United Therapeutics (UTHR) Q3 Earnings Beat but Stock Dips

United Therapeutics (UTHR) beats estimates for both earnings and sales in the third quarter but shares sink 10%.

United Therapeutics (UTHR) Q3 Earnings and Revenues Beat Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of 14.04% and 10.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q3 Earnings Preview: What's in the Cards?

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally

AcelRx (ACRX) earns majority votes from an FDA advisory committee, which recommends approval of Dsuvia for treating moderate-to-severe acute pain in adult patients.

Rigel (RIGL) Gets EMA Acceptance for Thrombocytopenia Drug

The EMA validates Rigel Pharmaceuticals' (RIGL) marketing application for thrombocytopenia drug, Tavalisse.

Neurocrine Inks Deal with Private Biotech to Make CNS Drugs

Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.